Posted by Michael Wonder on 30 May 2019
Arvinas receives fast track designation for its targeted protein degrader ARV-110 as a treatment for men with metastatic castration-resistant prostate cancer
29 May 2019 - Arvinas today announced that its lead Protac protein degrader, ARV-110, has been granted fast track designation by the U.S. FDA for the treatment of men with metastatic castration-resistant prostate cancer whose disease has progressed after treatment with two or more systemic therapies.
ARV-110 is an orally bioavailable Protac protein degrader designed to selectively target and degrade the androgen receptor protein.
ARV-110 is currently being evaluated in a Phase 1 clinical trial designed to evaluate the safety, tolerability, and pharmacokinetics of ARV-110 in men with metastatic castration-resistant prostate cancer whose disease has progressed after treatment with standard of care therapies.
